APOGEE THERAPEUTICS

apogee-therapeutics-logo

Apogee Therapeutics is a biotechnology company that offers therapies for immunological and inflammatory disorders. The company aims to advance novel therapies to address patientsโ€™ needs. Based in San Francisco, California, Apogee Therapeutics was founded in 2022.

#SimilarOrganizations #People #Financial #Event #Website #More

APOGEE THERAPEUTICS

Social Links:

Industry:
Biotechnology Life Science Medical Therapeutics

Founded:
2022-01-01

Address:
San Francisco, California, United States

Country:
United States

Website Url:
http://www.apogeetherapeutics.com

Total Employee:
101+

Status:
Active

Total Funding:
652 M USD

Technology used in webpage:
Google Maps Amazon IPv6 U.S. Server Location Google Maps API Amazon Virginia Region CloudFront GoDaddy SSL Akamai Hosted Equinix


Similar Organizations

affinia-therapeutics-logo

Affinia Therapeutics

Affinia Therapeutics is a biotechnology company developing transformative AAV gene therapies for people with devastating diseases.

carisma-therapeutics-logo

Carisma Therapeutics

Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors.

eikon-therapeutics-logo

Eikon Therapeutics

Eikon Therapeutics is a biopharmaceutical company that develops live-cell resolution microscopy and engineering for drug discovery.

nuvalent-logo

Nuvalent

Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer.

prime-medicine-logo

Prime Medicine

Prime Medicine operates as a biotechnology company that delivers the promise of gene editing using Prime Editing.

prolocor-logo

Prolocor

Prolocor is a biotechnology company that develops diagnostic tests for cardiovascular diseases.

tango-therapeutics-logo

Tango Therapeutics

Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.

verismo-therapeutics-logo

Verismo Therapeutics

Verismo Therapeutics develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer.


Current Advisors List

mark-mckenna_image

Mark McKenna Chairman of the Board of Directors @ Apogee Therapeutics
Board_member
2023-08-01

michael-henderson_image

Michael Henderson Board Member @ Apogee Therapeutics
Board_member

Current Employees Featured

jane-pritchett-henderson_image

Jane Pritchett Henderson
Jane Pritchett Henderson Chief Financial Officer @ Apogee Therapeutics
Chief Financial Officer
2023-01-01

michael-henderson_image

Michael Henderson
Michael Henderson Chief Executive Officer @ Apogee Therapeutics
Chief Executive Officer
2022-09-01

nimish-shah_image

Nimish Shah
Nimish Shah Co-Founder & Board Director @ Apogee Therapeutics
Co-Founder & Board Director
2021-12-01

Founder


nimish-shah_image

Nimish Shah

Stock Details


Company's stock symbol is NASDAQ:APGE

Investors List

rtw-investments-llc_image

RTW Investments

RTW Investments investment in Series B - Apogee Therapeutics

fidelity-investments_image

Fidelity

Fidelity investment in Series B - Apogee Therapeutics

deep-track-capital_image

Deep Track Capital

Deep Track Capital investment in Series B - Apogee Therapeutics

wellington-management_image

Wellington Management

Wellington Management investment in Series B - Apogee Therapeutics

orbimed-advisors_image

OrbiMed

OrbiMed investment in Series B - Apogee Therapeutics

perceptive-advisors_image

Perceptive Advisors

Perceptive Advisors investment in Series B - Apogee Therapeutics

venrock-healthcare-partners_image

Venrock Healthcare Capital Partners

Venrock Healthcare Capital Partners investment in Series B - Apogee Therapeutics

fairmount-funds-management_image

Fairmount Funds Management

Fairmount Funds Management investment in Series B - Apogee Therapeutics

ra-capital-management_image

RA Capital Management

RA Capital Management investment in Series B - Apogee Therapeutics

venrock-healthcare-partners_image

Venrock Healthcare Capital Partners

Venrock Healthcare Capital Partners investment in Series A - Apogee Therapeutics

Official Site Inspections

http://www.apogeetherapeutics.com Semrush global rank: 5.38 M Semrush visits lastest month: 1.4 K

  • Host name: aacb0a264e514dd48.awsglobalaccelerator.com
  • IP address: 75.2.70.75
  • Location: Seattle United States
  • Latitude: 47.54
  • Longitude: -122.3032
  • Metro Code: 819
  • Timezone: America/Los_Angeles
  • Postal: 98108

Loading ...

More informations about "Apogee Therapeutics"

Contact - Apogee Therapeutics

Apogee Therapeutics is a clinical stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and โ€ฆSee details»

Apogee Therapeutics - Crunchbase Company Profile

Apogee Therapeutics is a biotechnology company that offers therapies for immunological and inflammatory disorders. The company aims to advance โ€ฆSee details»

Investor Relations | Apogee Therapeutics, Inc.

Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for โ€ฆSee details»

APGE - Apogee Therapeutics, Inc. | Company Profile | OTC Markets

6 days ago apogeetherapeutics.com (650) 394-5230. [email protected]. Business Description. Apogee Therapeutics, Inc., through its subsidiary, operates as a โ€ฆSee details»

Apogee Therapeutics - LinkedIn

Apogee Therapeutics | 19,585 followers on LinkedIn. Apogee Therapeutics, LLC is a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of ...See details»

Apogee Therapeutics - Overview, News & Similar companies

Apogee Therapeutics contact info: Phone number: (650) 394-5230 Website: www.apogeetherapeutics.com What does Apogee Therapeutics do? Apogee Therapeutics, โ€ฆSee details»

Apogee Therapeutics - Company Profile - Tracxn

Feb 24, 2025 Apogee Therapeutics - Developer of therapeutics for immunological and inflammatory disorders. Public Company. Raised a total funding of $149M over 1 round from 7 โ€ฆSee details»

Apogee Therapeutics, Inc. - Drug pipelines, Patents, Clinical

Investor Contact:Noel KurdiVP, Investor Relations Apogee Therapeutics, [email protected] Media Contact:Dan Budwick 1AB โ€ฆSee details»

Apogee Therapeutics Provides Pipeline Progress and Reports Full โ€ฆ

Mar 3, 2025 For more information, please visit https://apogeetherapeutics.com. Forward Looking Statements. Certain statements in this press release may constitute โ€œforward-looking โ€ฆSee details»

Apogee Therapeutics | Meet the People that Power Progress

Apogee Therapeutics is a clinical stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), โ€ฆSee details»

Release Details - investors.apogeetherapeutics.com

For more information, please visit https://apogeetherapeutics.com. Forward Looking Statements Certain statements in this press release may constitute โ€œforward-looking statementsโ€ within the โ€ฆSee details»

Apogee Therapeutics - PitchBook

Apogee Therapeutics General Information Description. Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic โ€ฆSee details»

Our Science - Apogee Therapeutics

Mar 3, 2025 Our goal is to discover and develop novel therapies for a range of I&I diseases. We aim to accomplish this goal by focusing on known biologic drivers of disease and utilizing โ€ฆSee details»

Apogee Therapeutics Launches with $169 Million to Develop โ€ฆ

Dec 7, 2022 Apogee Therapeutics, LLC is a biotechnology company advancing novel, potentially best-in-class therapies to address the needs of the millions of people living with immunological โ€ฆSee details»

Apogee Therapeutics Launches with $169 Million to Develop

Dec 7, 2022 To learn more visit www.apogeetherapeutics.com. About Paragon Therapeutics. Paragon Therapeutics, Inc. is a biotechnology company leveraging cutting-edge science and โ€ฆSee details»

Apogee Therapeutics to Participate in Upcoming March Investor โ€ฆ

Feb 25, 2025 SAN FRANCISCO and BOSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE) today announced that members of management will โ€ฆSee details»

Apogee Therapeutics Provides Pipeline Progress and Reports

Dec 11, 2024 apogee therapeutics, inc. condensed consolidated statement of operations (unaudited) (in thousands) three months endedSee details»

Release Details - investors.apogeetherapeutics.com

Mar 3, 2025 Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody, exceeded trial objectives and demonstrated an approximately 60-day half-life APG279 โ€ฆSee details»

Apogee Therapeutics Highlights Progress and Best-in-Class โ€ฆ

Dec 2, 2024 Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep โ€ฆSee details»

Release Details - investors.apogeetherapeutics.com

Dec 2, 2024 Positive interim Phase 1 data indicate APG808 was well-tolerated with half-life of approximately 55 days, supporting potential for 2- to 3- month dosing and demonstrating deep โ€ฆSee details»

linkstock.net © 2022. All rights reserved